Conclusions: PTDM is associated with an unfavorable carPatient survival after renal transplantation: IV. Impact of postdiovascular risk profile that precedes the development of hytransplant diabetes.
perglycemia. PTDM is an independent predictor of reduced Background. The development of de novo diabetes mellitus survival in renal allograft recipients. is a serious complication of kidney transplantation. This study examined the cardiovascular risk profile of patients with posttransplant diabetes (PTDM) and assessed the impact of PTDM on patient survival.
Over the last three decades considerable improve-
Methods. This analysis included 1811 adult, renal allograft ments have been made in the survival of renal allografts recipients, transplanted in a single institution between 1983
[1] and of their recipients [2] . Still, compared to the and 1998. Patient survival was analyzed by univariable and multivariable Cox regression considering PTDM as a time de- general population, the survival of recipients of kidney pendent variable. transplants is significantly reduced [3] . This observation [4] . Recent studies showed that the cardiovascular risk P Ͻ 0.001), and included more African Americans (18 vs. factors that are relevant to the general public are also 28%, P ϭ 0.001). In addition, the incidence of PTDM was relevant to patients with kidney transplants [5] . In previsignificantly higher in patients who were transplanted after ous studies we initiated a systematic evaluation of vari-1995 than prior to that year. In contrast, there were no signifiables that correlate with the survival of kidney transplant cant differences between PTDM and patients who had DM before the transplant (DM; N ϭ 332). Compared to NoDM, recipients. Those studies led us first to the demonstration patients with PTDM had significantly higher total serum chothat dialysis prior to transplantation has a negative imlesterol and triglycerides (TG), higher systolic blood pressure pact on patient survival after transplantation [6] and also and higher pulse pressure throughout the post-transplant pethat smoking has a profound negative impact on the riod. Of interest, all of these abnormalities preceded the develsurvival of transplanted patients [7] . Our more recent opment of PTDM. Hypertriglyceridemia was particularly prostudies reported on variables that predispose patients to nounced in PTDM and elevated TG levels correlated with the subsequent development of PTDM, independent of other risk the development of post-transplant diabetes (PTDM) factors (P ϭ 0.001 by multivariate Cox). Compared to NoDM and found that the incidence of PTDM has increased (16% mortality) a significantly higher percent of DM (31%, sharply since 1995 [8] . Our current follow-up study as-P Ͻ 0.001) and PTDM (22%, P ϭ 0.005) patients died. By sessed the possible impact of PTDM on cardiovascular Cox regression, PTDM correlated with reduced patient survival risk and on patient survival after transplantation.
(hazard ratio ϭ 1.80, CI 1.35 to 2.41, P ϭ 0.001), and that relationship was independent of other correlates of reduced Post-transplant diabetes mellitus is thought to be the survival that included: increasing age; transplant year; reduced consequence of the development of insulin resistance serum albumin; and male sex. after transplantation [reviewed in 9, 10] . It is also possible, and perhaps more likely, that patients who developtions that the patient's characteristics prior to the transplant predispose to PTDM and that in many cases PTDM  2002 by the International Society of Nephrology Initiation of cyclosporine treatment post-transplant was delayed until the serum creatinine was Յ2.5 mg /dL. In mid 1995 all patients were started on cyclosporine develops within the first few weeks after transplantation [8] [9] [10] . If indeed patients with PTDM had insulin resismicroemulsion (Neoral) rather than Sandimmune. Furthermore, most patients who were on Sandimmune prior tance for a period of time prior to the development of DM, then we need to consider that the accelerated to that time were switched to Neoral. Prior to 1995 most patients received azathioprine (Imuran) in addition to development of cardiovascular disease likely started at the time of initiation of insulin resistance, prior to the cyclosporine. However, since 1995 all patients received mycophenolate mofetil (CellCept) instead of azathiodevelopment of hyperglycemia, because insulin resistance itself is associated with an increased cardiovascular prine as part of a triple immunosuppression protocol that also included Neoral and prednisone. None of the risk [11] .
Insulin resistance is associated with complex metabolic patients included in this study were treated with FK506 (Prograf) or with sirolimus (Rapamycin). and hemodynamic abnormalities, including [11, 12] truncal obesity; hypertension; dyslipidemia; elevated procoClinical data were obtained mainly from an electronic database that contains all of the clinical and laboratory agulant factors [13] ; and elevated insulin levels. Several factors may cause-or worsen-insulin resistance in reinformation in our patients. In the majority of patients, only the levels of total serum cholesterol and triglycernal allograft recipients, including: (1) renal insufficiency [14, 15] ; (2) the effects of corticosteroids and calcineurin ides (TG) were obtained routinely. Thus, data on lowdensity lipoprotein (LDL) and high-density lipoprotein inhibitors [reviewed in 9, 16]; and (3) the frequent development of obesity after transplantation [17] . In this study (HDL) cholesterol were not analyzed in this study. Serum albumin values were analyzed as the average serum we assessed several of the features of the insulin resistance syndrome in renal transplant recipients.
concentration from months 6 to 18 post-transplant. Blood pressures (BP) were measured by the patient at home and reported to the post-transplant office. BP determina-METHODS tions made during outpatient clinic visits were also inPatient population cluded in the analysis. Mean arterial pressure (MAP) was calculated as [(systolic BP Ϫ diastolic BP)/3) ϩ diaThe study population included 1811 patients who received their first kidney transplants at The Ohio State stolic BP]. Pulse pressure (PP) was calculated as systolic BP Ϫ diastolic BP. University between 1983 and December 1997, and who maintained graft function for at least six months postStatistical analysis transplant. The mean follow-up for the population was 8.3 Ϯ 4.5 years. These patients were subdivided into Data in the manuscript are expressed as means Ϯ standard deviation of the mean unless indicated otherthree groups: (1) patients without diabetes before and after the transplant (NoDM, N ϭ 1186, 66%); (2) patients wise. Proportions were compared by Chi square analysis. Mean values in two groups were compared by the Stuwho had diabetes prior to the transplant (DM, N ϭ 332, 18%); and (3) patients who developed de novo DM dent t test or by a non-parametric test if the data were not normally distributed. Mean values in more than two after the transplant (PTDM, N ϭ 293; 20%). PTDM was diagnosed when transplanted patients who previously groups were compared by analysis of variance (ANOVA) or by the Mann-Whitney test if the data were not norwere not diabetic required treatment of hyperglycemia with either oral hypoglycemic agents and/or insulin. One mally distributed. Patient survival was analyzed by both univariate and multivariate Cox regression and displayed hundred and twenty-eight patients met these criteria but were not included in the PTDM group, because a review in Kaplan-Meier plots. Patient survival was censored at the time of graft loss. The correlation between PTDM of these charts revealed that these patients were hyperglycemic even at the time of transplantation although and patient survival was analyzed by Cox regression where PTDM was considered a time dependent variable, they were not taking hypoglycemic drugs. Table 1 dis-because this complication started at different times following the transplant. To assure that the Cox models were correctly interpreted, the assumption of proportional hazards was formally tested. Table 1 displays the overall characteristics of the patient population and the characteristics of each of the patient groups. As can be seen, and as shown previously [8] , compared to the NoDM group, patients who developed PTDM were significantly older, significantly heavier, and included a significantly higher percent of recipients of African American race. In contrast, there were no significant differences between PTDM and DM patients in any of these characteristics ( Table 1 ). As shown previously the incidence of PTDM also correlated with the year of transplant. Thus, PTDM developed more frequently in patients transplanted since 1995 than before that year [8] . Additional comparisons between these patient groups have been reported previously [8] .
RESULTS

Demographic characteristics of the patient population
After a period of follow-up of 8.3 Ϯ 4.5 years 20% of the patients died and 14% lost their grafts for reasons other than patient death. Throughout the post-transplant period 293 out of 1479 patients who were not diabetic before the transplant developed PTDM (20%).
Dyslipidemia
Figure 1 displays average yearly total serum cholesterol and serum TG concentrations post-transplant in patients who were followed for the entire period of time (B) Serum triglyceride (TG) levels (mean Ϯ SEM) in the same groups shown in the figure, that is, six years. As can be seen in of patients. Figure 1A , the concentration of total serum cholesterol increased significantly during the first year post-transplant in all groups of patients. Thereafter, serum cholesterol levels declined progressively in all patient groups. ceded the development of diabetes. This is shown in Figure 2 where serum TG levels are displayed in two groups Compared to NoDM, cholesterol concentrations were significantly higher in PTDM at years one, two and three of patients: NoDM and PTDM before they developed diabetes. As can be seen, compared to patients with (P Յ 0.01, Kruskall-Wallis). In contrast, cholesterol values were not significantly different in PTDM and in DM.
NoDM, serum TG levels were significantly higher, at years 1 through 4, in PTDM. After the fourth year, the Serum TG levels (Fig. 1B) were significantly higher in PTDM than in NoDM throughout the post-transplant numbers of patients in the PTDM group was small (N Ͻ 50) and thus this analysis was not done on later years. period (P Ͻ 0.0001 on years 0 to 4; P Ͻ 0.01 on years 5 and 6, Kruskall-Wallis). Serum TG in patients with DM Because hypertriglyceridemia preceded the development of PTDM, we next examined whether serum TG were generally lower than those of PTDM and higher than those in NoDM. These differences in lipid levels levels correlated with the development of PTDM. The results of a multivariate analysis, including other variwere not caused by differences in the frequency of use of lipid lowering agents. In fact, these drugs were used ables shown previously to correlate with the development of PTDM [8] are shown in Table 2 . As can be seen, significantly more commonly in patients with PTDM (53% of patients) than in DM (31%) or in NoDM (28%) elevated serum TG levels correlate significantly with a higher incidence of PTDM and that correlation was inde-(P Ͻ 0.001 by Chi square).
In patients with PTDM, hypertriglyceridemia prependent of other variables, including increasing age; in- a RR ϭ relative risk that was calculated for every 10 years of age, or every 10 kg of weight or every 10 mg/dL increase in serum TG levels b Weight was included in this analysis, rather than the BMI, because the dataset is more complete for this parameter than for BMI values c Patients in this study were transplanted between 1983 and 1998; the incidence of PTDM has increased significantly in recent years, particularly since 1995 [8] creasing weight; African American race; and more recent transplant year. Regarding the latter variable, we showed previously that, compared to patients transplanted prior to 1995, the incidence of PTDM after that year increased significantly [8] . The correlation between serum TG 250 and 600 mg/dL and 36% of the patients with TG Ն 600 mg/dL (P ϭ 0.02 by 2 analysis).
Blood pressure levels 3B displays the evolution of the diastolic BP in the three groups of patients. This parameter did not differ signifi- Figure 3 displays the evolution of average yearly BP cantly between the NoDM and the PTDM groups. Howvalues throughout the post-transplant. As can be seen ever, it is notable that patients in the DM group had in Figure 3A , the systolic BP declined sharply during the significantly lower diastolic BP than the other two groups first year post-transplant in all three groups of patients, of patients, except on years 5 and 6 post-transplant (P Ͻ and thereafter it remained relatively unchanged. The 0.0001, ANOVA). Finally, Figure 3C displays the evolusystolic BP was not significantly different in PTDM and tion of the pulse pressure. Compared to NoDM, pulse DM. However, these two groups of patients had higher pressure was significantly higher in DM and in PTDM systolic BP than NoDM at all time points (P Ͻ 0.0001 by ANOVA except years 4 and 5, P Ͻ 0.002). Figure at all time points (P Ͻ 0.0001, ANOVA). A comparison between the pulse pressure values in patients in the DM and PTDM groups revealed the following findings: The pulse pressure was significantly lower in PTDM than in DM at years 0 (P Ͻ 0.0001) and two (P ϭ 0.01). However, after year two the pulse pressure rose progressively in patients with PTDM and it became not significantly different than the pulse pressure of patients with DM. The BP changes observed in patients with PTDM preceded the development of diabetes. Thus, at one year post-transplant the systolic BP was significantly higher in patients who later developed PTDM than in NoDM (143 Ϯ 13 vs. 139 Ϯ 13 mm Hg, P ϭ 0.002) and that difference persisted at two years (137 Ϯ 14 vs. 133 Ϯ 14, P ϭ 0.006). Significant differences were also observed on the pulse pressure in years one and two post-transplant (data not shown).
Patient survival
During the follow up period, 16% of NoDM patients died compared to 31% of DM (P Ͻ 0.0001 by 2 ) and 22% of PTDM (P ϭ 0.01). The cause of death was known in approximately 50% of the patients in each group. Compared to NoDM, patients with DM had a significantly higher percent of cardiovascular deaths (49 vs. 69%, P ϭ 0.02). However, the number of cardiovascular deaths was not significantly different in NoDM (49%) and PTDM (54%). The degree of glucose control, measured as the average HbA1c during the follow-up period, did not correlate with mortality in either DM or PTDM patients (data not shown). Figure 4 displays Kaplan-Meier patient survival plots in the three groups of patients. The first analysis plotted (Fig. 4A) .
(thin line), DM (thick line) and PTDM (dashed line). (A) Survival was
As can be seen, survival was significantly worse in DM calculated from the day of transplantation in all three groups of patients. than in either NoDM or PTDM (log rank P Ͻ 0.0001 (B) Survival for PTDM was calculated from the time of development of diabetes and for the other two groups from the day of transplantation. both). The survival plots for patients with PTDM and NoDM overlapped for approximately 96 months and thereafter those plots diverged such that, overall, the survival of PTDM was significantly lower than that of elevated total serum cholesterol; elevated triglycerides; NoDM (P ϭ 0.04 by log rank). A second analysis plotted and elevated systolic BP during the follow-up period. survival in patients with PTDM from the time of developIn addition, there were significant correlations between ment of diabetes, and compared with the survival in DM reduced patient survival and lower diastolic BP (RR ϭ and NoDM calculated from the transplant day (Fig. 4B) .
0.979, P ϭ 0.002) and/or higher pulse pressure (RR ϭ As can be seen, the survival plots for DM and PTDM 1.029, P Ͻ 0.0001). Other variables that did not correlate are superimposable and significantly different from the significantly with patient survival included: recipient survival of NoDM (P Ͻ 0.0001 by log rank).
race; donor age, race or gender; number of acute rejec- Table 3 displays the variables that, by Cox analysis, tion episodes; graft function at six months post-transcorrelate significantly with patient survival in this popuplant; and histocompatibility parameters. lation. It should be noted that in these analyses PTDM In a multivariate analysis, including only those patients was analyzed as a time dependent variable. By univariate who were not diabetic prior to the transplant (Table 3) , analysis the variables that correlated with reduced pa-PTDM was a significant correlate of reduced patient tient survival included: older age; male recipient; remote survival independently of other variables, including rerather than more recent transplant year; reduced serum cipient age and gender, and serum albumin. The transalbumin during the first year post-transplant; DM pretransplant; the development of PTDM; heavier recipient; plant year was not added to this model because we found African Americans. Perhaps this inconsistency in approach reflects an incomplete appreciation of the poten-DISCUSSION tially devastating consequences of PTDM for transplant The results of this study are consistent with the interrecipients. pretation that PTDM is the final manifestation of a comIn addition to elevated TG levels, patients with PTDM plex metabolic profile that is thought to be the consehad an unfavorable cardiovascular risk profile that inquence of resistance to the actions of insulin [12] . This cluded obesity, elevated total serum cholesterol, elevated syndrome has received several names including synsystolic blood pressure, and elevated pulse pressure. Of drome X, insulin resistance syndrome, and dyslipidemia interest, these parameters did not differ significantly besyndrome. Understanding PTDM as a late manifestation tween patients with PTDM and patients with DM prior of the insulin resistance syndrome provides a reasonable to the transplant, which is striking because DM is statistiexplanation for the observation made in our current cally the strongest predictor of patient survival after restudy that, in transplant recipients, the metabolic (dyslipnal transplantation (for example, [6] ). Perhaps this lack idemia) and hemodynamic (hypertension and widened of difference in cardiovascular risk profile explains the pulse pressure) abnormalities associated with PTDM preobservation made here that, calculated from the time of cede the development of hyperglycemia. development of PTDM, the survival of PTDM and DM In previous studies we discussed the variables that patients do not differ significantly. Furthermore, the hazcorrelate with the development of PTDM [8] . Those ard ratio for DM and PTDM were quite similar (2.1 and variables include increasing age, increasing weight, Afri-1.88, respectively). can American race, and a transplant done in recent years.
Among the cardiovascular risk factors considered in To that list we now add another independent variable, our current study, it was of particular interest to observe the presence of elevated serum TG levels, which correthe evolution of the pulse pressure in patients with DM late with the subsequent development of hyperglycemia, or PTDM. Pulse pressure was significantly higher during that is, PTDM. It is hoped that the recognition of factors the first years post-transplant in DM than in PTDM, that predispose to PTDM will encourage the use of postbecause the diastolic BP was significantly lower in patransplant management strategies that could minimize tients with DM. This observation is of interest because, the risk of PTDM. For example, the literature emphaas shown here and also in previous studies [21, 22] , low sizes the diabetogenic effects of chronic corticosteroid diastolic BP, particularly in association with high systolic use and the more potent diabetogenic effects of FK506, BP, correlates with an increased cardiovascular risk. compared to cyclosporine, particularly in African AmeriWith increasing time post-transplant, the pulse pressure cans [18, 19] . Indeed, the diabetogenic effect of steroids rose in patients with PTDM until it reached values that is one of the principal reasons for the current emphawere not significantly different from values found in pasis on the application of steroid withdrawal immunotients with DM. Pulse pressure is now recognized as a suppressive protocols following transplantation [20] . In statistically strong correlate of CV risk [23, 24] . Because the measured CV risk factors were abnormal contrast, the potent diabetogenic effect of FK506 is
